about

Enabling Control Over the Chemical Space

Deep LS GmbH, founded in 2021 by Daniel Soric and Felix Kamieth, operates at the intersection of artificial intelligence and pharmaceutical research. The founders identified a significant opportunity to accelerate the traditionally lengthy and costly drug discovery process by leveraging advanced digitalization and AI. The company provides AI-powered software and tools designed to predict and optimize molecules for biopharmaceutical research, targeting clients such as pharmaceutical and biotech companies. Deep LS is headquartered in Limburg, Germany, and has secured funding from entities including BIRD Incubator, Hessian AI, and ESA Commercialisation GATEWAY. The core of Deep LS's offering is its proprietary software platform, GeneSys, which utilizes generative AI methods like latent diffusion to generate novel drug candidates tailored to specific target proteins. This platform assists researchers in designing molecules by generating ligands that fit a specified target molecule and optimizing them for critical properties such as toxicity and solubility. The software covers multiple sub-processes in drug development, allowing for seamless integration of new findings throughout the research pipeline. The company's services include a 'Generative Ligand Finder' for designing small molecules, peptides, or proteins; 'Feature Assessment' for analyzing and optimizing compounds; and 'Binding Site Identification' on proteins or RNA. This technology is not only applicable to the pharmaceutical industry but also holds potential for sectors like crop protection, chemicals, cosmetics, and food supplements. Deep LS currently operates on a project-based business model but is planning to transition to a platform model with recurring revenues from software licenses. The company also anticipates generating licensing income from molecules that are jointly developed with partners. Significant projects include the 'Chemical Space Navigator' for optimizing drug candidates and 'Plant Graph Target Discovery' for agricultural science applications. In June 2025, a collaborative project with the Technical University of Darmstadt received €338,300 in LOEWE funding to advance AI-supported, structure-based drug development, specifically targeting the protein FKBP51, which is relevant for diseases like depression and neuropathic pain. Keywords: drug discovery, artificial intelligence, machine learning, computational drug discovery, molecule optimization, generative AI, biopharmaceutical research, ligand design, small molecule discovery, protein targeting, pharmaceutical technology, toxicity prediction, solubility optimization, drug development platform, biotech startup, ADMET prediction, latent diffusion models, computational chemistry, bioinformatics, structure-based drug design